2024 Equity Equity Financing 
Reynolds Holding
JUNE 3, 2024
By the end of 2022, add-on acquisitions represented more than 76% of all private-equity-backed buyouts, which was a significant increase compared to a decade earlier. The percentage of add-ons dipped by 1% in 2023 — a year when volume and value of buyouts dropped significantly — and reached 76% in the first three months of 2024.
Benzinga
JULY 11, 2024
Pursuant to a binding subscription agreement dated July 9, 2024 (the " Subscription Agreement "), the Acquiror has acquired deemed beneficial ownership (in accordance with section 1.8 per Acquired Share for aggregate consideration of C$64,920,698.50 (the " Equity Financing "). Vancouver, British Columbia, V7X 1M3.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Benzinga
OCTOBER 22, 2024
22, 2024 (GLOBE NEWSWIRE) -- Orthobiologics Market size was valued at USD 6.43 during the forecast period (2024-2031). during the forecast period (2024-2031). The firm closed a round of equity financing for USD 12.7 Forecast Period 2024–2031 Full story available on Benzinga.com Westford, USA, Oct.
Benzinga
AUGUST 12, 2024
Preparing for the Future: Financing package includes equity raise to preserve flexibility for future growth. million), reflects POWER's estimated 2024 pre-IFRS 16 adjusted EBITDA 3 at a multiple of 15.2x, or 12.5x The Acquisition is expected to be completed in the early fourth quarter of 2024. post-synergies 4.
Benzinga
AUGUST 28, 2024
28, 2024 (GLOBE NEWSWIRE) -- Tactical Resources Corp. Proposed Business Combination As previously announced, Tactical Resources entered into a definitive business combination agreement (the "Business Combination Agreement") with Plum on August 22, 2024. VANCOUVER, British Columbia, Aug. million, calculated on a fully diluted basis.
Benzinga
NOVEMBER 13, 2024
13, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. Upon completion of the Proposed Merger, the shareholders of Journey will acquire 99% of the equity of Entero. Markovic, M.D., The combined company is expected to operate under the name Journey Therapeutics, Inc., and will apply for continued trading on The Nasdaq Capital Market.
Benzinga
APRIL 22, 2024
per RGD common share, an estimated Transaction equity value of $875 million, based on the closing price of GMIN common shares on the Toronto Stock Exchange (" TSX ") on April 19, 2024, excluding the value of the SpinCo consideration. RGD shareholders will receive estimated consideration of $0.65
Expert insights. Personalized for you.
45 
Let's personalize your content